- Novartis reports that it has reached a “definitive agreement” to buy the Fort Worth, Texas-based Encore Vision, who are developing EV06, a lens softening presbyopia treatment. Financial details of the transaction have not been disclosed.
- Heidelberg Engineering has finally launched its Spectralis OCT angiography module. Currently available in ex-US markets, the unit is designed to be used with new and existing Spectralis devices.
- The 21st Century Cures Act has been passed by the US Congress, after almost three years of waiting. The landmark legislation is intended to fast-track the introduction of new therapies by boosting federal funding and accelerating FDA approval processes.
- The European Commission has granted Novartis approval for the use of ranibizumab in choroidal neovascularization stemming from causes other than neovascular age-related macular degeneration, and choroidal neovascularization secondary to pathologic myopia.
- Bayer and Versant Ventures have announced the launch of BlueRock Therapeutics, a company focused on stem cell therapies, and have committed US$225 million in funding.
- Private investment company Ardian has acquired a majority stake in SCHWIND eye-tech-solutions. Rolf Schwind will continue as CEO and retains a significant interest in the company.
False
Advertisement
Related Content
Newsletters
Receive the latest Ophthalmology news, personalities, education, and career development – weekly to your inbox.
False
Advertisement